Advertisement
Response from Dr. Sherer

First, I agree with your doctor that a resumption of
efavirenz is a reasonable choice, since you tolerated
it and appartently had a positive experience with it
in the past. My answer would change if this latter
statement were incorrect.
Based on results from the Gilead 903 study, and the
comparability of clinical outcomes with FTC and 3TC,
I think that is a useful regimen for at least 2 years.
My only hesitation would be if you had any degree of
kidney disease, in which care should be taken with
Viread. You should talk to your doctor about this.
Secondly, I agree with you that it would be prudent
to get a resistance test - a genotype, in this case -
before resuming therapy. Understand that a test result
which shows 'wild type' might not truly represent the
presence of mutations, as most viruses containing
mutations will 'revert', i.e. be overwhelmed by, wild
type virus. The resistance mutation may nonetheless
be present, i.e. 'archived', and show itself under the
selective pressure of the regimen. Time will tell, but
the odds are good that you will remain susceptible
to this regimen.
You and your doctor will watch your progress closely,
and repeat a genotype test if needed if and when your
response appears sub-optimal.
I recommended a genotype in this case because the sentinel
mutations of interest here - NNRTI mutations, the M184V for
3TC, and the K65R (among others) for abacavir - are unambiguous.
Again, you should talk to your doctor, as his or her preference
may differ.
Want to read more questions and answers on this subject? Our experts have answered many similar questions!
|